

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

D. Charytan reports the following:

Employer: New York University School of Medicine;; Consultancy: Eli Lilly/Boehringer Ingelheim, Astra Zeneca, Allena Pharmaceuticals (DSMB), Gilead, Novo Nordisk, GSK, Medtronic, Merck, CSL Behring, Zogenix, Renalytix, LG Chemical, Alentis Therapeutics; Research Funding: Medtronic-clinical trial support; Gilead; NovoNordisk; Amgen, Boehringer Ingelheim/Eli Lilly; Patents or Royalties: UpToDate.com for authorship/editorials on reviews; Advisory or Leadership Role: CJASN; and Other Interests or Relationships: Expert Witness Fees Related to Proton Pump Inhibitors and anti-depressants.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: David M. Charytan

Manuscript ID: K360-2024-000115R3

Manuscript Title: Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study

Date of Completion: June 19, 2024

Disclosure Updated Date: June 19, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

A. Costea reports the following:

Employer: the christ hospital

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Alex I Costea

Manuscript ID: K360-2024-000115R3

Manuscript Title: Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study"

Date of Completion: August 1, 2024

Disclosure Updated Date: August 1, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

V. Kher reports the following:

Employer: Self employed; Consultancy: Torrent pharmaceuticals, India; Novartis , India; Roche, India; Panacea,India; Sanofi Aventis, India; Intas pharmaceuticals, India; Biocon pharmaceuticals , India ; GSK, India; RPG Life Sciences; Astra-zenaca , India, Zydus pharmaceuticals, India; Research Funding: Novartis India, Sanofi Aventis India, Astellas India; Medtronics, zydus Pharmaceuticals, India; Honoraria: Novartis, India; Roche India ; Astellas, India; Torrent, India; Reddy's India; Intas India; JB pharmaceuticals India;; Advisory or Leadership Role: ROCHE INDIA, NOVARTIS INDIA, TORRENT, SANOFI AVENTIS,Reddys India, Biocon india Medtronics; Wockhardt, India, Zydus India, intas , India; Speakers Bureau: Novartis, India; Roche, India; Panacea, India; Sanofi Aventis, India; Intas, India; Biocon, India; Pfizer; Johnson and Johnson; JB pharmaceuticals; Astra-zenaca , India; Boehringer Ingelheim India, IPCA pharmaceuticals, India, Abbott , India.; and Other Interests or Relationships: Kidney health ,education and research society, India; Kidney education and research network : non-profit NGOs; Regional coordinator research South Asia, International society of nephrology; Advisory board Indian Journal of Nephrology, Indian Journal of transplantation.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Vijay K. Kher

Manuscript ID: K360-2024-000115R1.

Manuscript Title: Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study

Date of Completion: May 6, 2024

Disclosure Updated Date: May 6, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

B. Koplan reports the following:

Employer: Brigham and Women's Hospital; and Consultancy: GE Healthcare.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Bruce A. Koplan

Manuscript ID: K360-2024-000115R3

Manuscript Title: Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study

Date of Completion: July 10, 2024

Disclosure Updated Date: July 10, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

F. McCausland reports the following:

Employer: Brigham and Women's Hospital; Consultancy: GlaxoSmithKline; Zydus Therapeutics Inc.; Research Funding: Research Funding paid to institution from NIDDK, Satellite Healthcare, Novartis, Lexicon, and Fifth Eye.; and Other Interests or Relationships: Expert witness fees from Rubin-Anders scientific.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Finnian R. McCausland

Manuscript ID: K360-2024-000115R2

Manuscript Title: Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study

Date of Completion: May 29, 2024

Disclosure Updated Date: March 6, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

C. McClure reports the following:

Employer: NAMSA, Broadcom; and Ownership Interest: Broadcom.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Candace McClure

Manuscript ID: K360-2024-000115R2

Manuscript Title: Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study

Date of Completion: May 29, 2024

Disclosure Updated Date: May 21, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

K. Ravi reports the following:

Employer: Brigham and Women's Hospital; and Ownership Interest: Halo LLC (spouse).

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Katherine Scovner Ravi

Manuscript ID: (K360-2024-000115R2)

Manuscript Title: Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study

Date of Completion: May 28, 2024

Disclosure Updated Date: March 6, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

P. Roy-Chaudhury reports the following:

Employer: 1. University of North Carolina; 2. VAMC Salisbury, NC; Consultancy: WL Gore, Medtronic, Becton Dickinson, Cormedix, Humacyte, Akebia, Astra-Zeneca, Alexion (Astra-Zeneca Rare Diseases), Bayer, Panoramic Health; Ownership Interest: Chief Scientific Officer and Founder, Inovasc LLC; Research Funding: NIH Small Business Grants as MPI or site PI with;; Inovasc, Adgero, Cylerus, Sojourn and Eko; Honoraria: WL Gore, Medtronic, Becton Dickinson, Cormedix, Humacyte, Akebia, Astra-Zeneca, Alexion (Astra-Zeneca Rare Diseases), Bayer, Panoramic Health; Patents or Royalties: Method for Making Magnesium Biodegradable Stent for Medical Implant Applications?, International Application No. PCT/US 1332374, March 15, 2011; and Advisory or Leadership Role: ASN, Vascular Access Society of the America's, WL Gore, Medtronic, Becton Dickinson, Cormedix, Humacyte, Akebia, Astra-Zeneca, Alexion (Astra-Zeneca Rare Diseases), Bayer, BioMed Innovations, N9, Panoramic Health, Editorial Board, Journal of Vascular Access.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Prabir Roy-Chaudhury

Manuscript ID: K360-2024-000115R3

Manuscript Title: "Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study."

Date of Completion: June 15, 2024

Disclosure Updated Date: March 1, 2024



## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

J. Tumlin reports the following:

Employer: NephroNet Clinical Trials Consortium; Consultancy: NephroNet Clinical Trials Consortium, Mallinckrodt Pharmaceuticals, Liliy Pharmaceuticals, Relypsa Pharmaceuticals, Astra Zeneca Pharmaceuticals, Alexion Pharmaceuticals, Astra Zeneca Pharmaceuticals, Alpine Pharmaceuticals, Vera Pharmaceuticals, Vertex Therapeutics. Alexion Pharmaceuticals, HIBAR Microsciences LLC, Calliditas Therapeutics. Traverre Pharmaceuticals.; Research Funding: NephroNet Clinical Trials Consortium, Mallinckrodt Pharmaceuticals, Johnson& Johnson, LaJolla Pharmaceuticals, Abbvie Pharmaceuticals, ZS Pharmaceuticals. Achillion Pharmaceuticals, Relypsa Pharmaceuticals, Epizon Pharmaceuticals, Gilead Pharmaceuticals, Astra Zeneca; Akebia Pharmaceuticals. Vinterra Pharmaceuticals., Alpine Pharmaceuticals, Horizon Pharmaceuticals; Honoraria: Mallinckrodt Pharmaceuticals, Genentech, Alexion Pharmaceuticals, Genzyme Corp. Astra Zeneca Pharmaceuticals.; Aurinia Pharmaceuticals; Astra Zeneca Pharmaceuticals. Bayer Pharmaceuticals Alpine Pharmaceuticals, Calliditis Therapeutics; Patents or Royalties: HIBAR Microsciences LLC; Advisory or Leadership Role: Achillion Pharmaceuticals, Relypsa Pharmaceuticals, Epizon Pharmaceuticals, Gilead Pharmaceuticals, KBP Pharmaceuticals.; Alexion Pharmaceuticals; Bayer Pharmaceuticals, Chemocentryx and Bayer Corp. Aurinia Pharmaceuticals, Vera Therapeutics; and Speakers Bureau: Mallinckrodt, La Jolla Pharmaceuticals and Alexion Pharmaceuticals, Astra Zeneca Pharmaceuticals; Aurinia Pharmaceuticals Bayer Pharmaceuticals, Bayer Corporation, Callidatis Pharmaceuticals Traverre Pharmaceuticals.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: James A. Tumlin

Manuscript ID: K360-2024-000115R3

Manuscript Title: "Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study,

Date of Completion: July 8, 2024

Disclosure Updated Date: July 8, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

D. Williamson reports the following:

Employer: CloudCath; Ownership Interest: Cloudcath; Advisory or Leadership Role: New England NKF Medical Advisory Board; CloudCath- CMO; and Other Interests or Relationships: National Kidney Foundation New England Chapter Board Member.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Don E. Williamson

Manuscript ID: K360-2024-000115R3

Manuscript Title: Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis (MiD) Study

Date of Completion: June 15, 2024

Disclosure Updated Date: June 15, 2024